Related Experiment Video
Updated: Feb 1, 2026
Recurrent Herpetic Stromal Keratitis in Mice, a Model for Studying Human HSK
Published on: December 18, 2012
Juvenile-Onset Recurrent Respiratory Papillomatosis and Human Papillomavirus Vaccine Uptake: A 19-Year Retrospective
Alexandra F Corbin1, Nick Sahlollbey2, Gaayathri Varavenkataraman3
1Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo, Buffalo, New York, USA.
Objective:
To evaluate 19-year trends in juvenile-onset recurrent respiratory papillomatosis incidence and treatment utilization in the context of increasing human papillomavirus vaccine uptake.
Study Design:
Retrospective cohort study.
Setting:
TriNetX United States Collaborative Network.
Methods:
Children 18 years of age or younger with juvenile-onset recurrent respiratory papillomatosis diagnosed between January 1, 2006, and December 31, 2024, were identified using International Classification of Diseases codes. Annual encounter-based incidence per 100,000 patients was calculated for both juvenile-onset recurrent respiratory papillomatosis and human papillomavirus vaccination. Within the pediatric juvenile-onset recurrent respiratory papillomatosis cohort, annual utilization of major treatment modalities, including bevacizumab, cidofovir, lesion excision, and tracheostomy, was assessed.
Results:
A total of 1854 children met inclusion criteria (mean age 7.9 ± 5.7 years). Juvenile-onset recurrent respiratory papillomatosis incidence declined by 65.2%, from 3.1 cases per 100,000 in 2006 to 1.1 cases per 100,000 in 2024 (P < .001). Human papillomavirus vaccine incidence increased by 1448.1%, from 45.5 to 704.4 cases per 100,000 patients over the same period (P < .001). Annual juvenile-onset recurrent respiratory papillomatosis incidence was inversely correlated with human papillomavirus vaccine incidence (r = -0.892; P < .001). Within the pediatric juvenile-onset recurrent respiratory papillomatosis cohort, use of bevacizumab and cidofovir increased significantly, whereas lesion excision and tracheostomy incidence remained stable.
Conclusion:
Rising human papillomavirus vaccine uptake is associated with a significant reduction in encounter-based juvenile-onset recurrent respiratory papillomatosis incidence at the population level. Surgical excision remains the predominant management approach, with limited adoption of adjuvant therapies despite recent increases.
Related Concept Videos
01:51Vaccinations
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:31Anatomy of Respiratory System II: Lower Respiratory Tract
The Larynx
It is located between the pharynx and the trachea, acts as a passageway for air, and hosts several critical structures, such as the epiglottis, vocal cords, and glottis. The epiglottis acts as a gateway, guiding food to the...
01:16The Respiratory System
01:16Other Nuclides: 31P, 19F, 15N NMR
While fluorine-19 and phosphorous-31 have high natural abundances (100%) and positive gyromagnetic ratios, nitrogen-15 has a low natural abundance and a negative gyromagnetic ratio. However, nitrogen-15 is still preferred over nitrogen-14 (which has a...
01:29Anatomy of Respiratory System I: Upper Respiratory Tract
Nose and nasal cavity
The nose and nasal cavity represent the main external openings of the respiratory tract....